Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy, Safety And Immunogenicity of Vaccination With ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years
Latest Information Update: 23 Jul 2024
At a glance
- Drugs JNJ-78901563 (Primary)
- Indications Escherichia coli infections
- Focus Registrational; Therapeutic Use
- Acronyms E.mbrace
- Sponsors Janssen Research & Development; Janssen Vaccines and Prevention B.V
- 08 Mar 2024 This trial has been Discontinued in Italy according to European Clinical Trials Database record.
- 08 Mar 2024 This trial has been Discontinued in Italy according to European Clinical Trials Database record.
- 08 Mar 2024 This trial has been Discontinued in Italy according to European Clinical Trials Database record.